Your search for apixaban returned 68 results

Andexxa, a recombinant modified human Factor Xa (FXa) protein, was approved under the FDA’s Accelerated Approval pathway.

The study analyzed data from NVAF patients newly initiating treatment with dabigatran, rivaroxaban or apixaban.

The greatest risk reduction of stroke or systemic embolism was seen with dabigatran 150mg twice daily (odds ratio [OR] 0.65, 95% CI: 0.52-0.81), followed by apixaban 5mg twice daily (OR 0.79, 95% CI: 0.66-0.94).

Compared with warfarin, dabigatran and rivaroxaban linked to lower risk of adverse renal outcomes

And antithrobotic medications linked to higher rate of hematuria-related events in older adults

The main outcomes and measures were intraocular bleeding events and associated risk ratio for NOACs, compared with warfarin.

The recall is specific to Eliquis 5mg Tablets (60-count bottle) Lot# HN0063 with expiration date of September 2019.

Study of newer medications finds 16 percent receive too much or too little

The researchers found the risk of GI bleeding was lower for apixaban versus dabigatran or rivaroxaban.

Patients taking apixaban showed significantly less intracranial hemorrhage (0.33% per year) vs. patients taking warfarin (0.80% per year) no matter the type and location.